SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as retail investors react to a combination of workforce restructuring, record-breaking trading volumes, and bullish anticipation for new revenue streams like AI-driven trading tools and prediction markets. Community members are actively debating the stock's potential for a breakout, with many focusing on the impact of increased platform engagement during major sporting and market events.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors closely monitor a high-stakes legal dispute with Nippon Shinyaku regarding the distribution rights for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively discussing the impact of this litigation on the upcoming August PDUFA date, with many bullish investors framing the lawsuit as a strategic catalyst that could return full commercial rights to Capricor ahead of the drug's anticipated approval.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing significant volatility as market participants debate the stock's massive valuation and its status as a high-profile IPO. The community is sharply divided, with many retail investors expressing concerns over a potential "rug pull" and long-term downside, while others view the pullback as a buying opportunity.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant institutional interest as the community anticipates imminent Phase 3 52-week data, which is widely viewed as a major catalyst for potential M&A activity. Traders are actively discussing the stock's tight float and the strategic significance of recent supply agreements alongside upcoming conference presentations.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing heightened trading volume and volatility as investors speculate on potential data center tenant agreements amid ongoing boardroom leadership conflicts. Community sentiment remains polarized, with some traders optimistic about the company's energy infrastructure assets while others are wary of the persistent management drama and the lack of confirmed commercial contracts.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is facing intense community skepticism and frustration as the stock continues to trade near all-time lows despite sustained revenue generation. Investors are actively debating potential buyout scenarios and the impact of the company's siRNA pipeline while pointing to perceived management incompetence and heavy short interest as primary drivers of recent volatility.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging after the FDA reversed its previous stance and now allows the company to use three-year Phase I/II data for an accelerated approval BLA filing, effectively pulling forward the commercialization timeline for its Huntington's disease gene therapy. The community is actively discussing the significant regulatory win and the potential for a rapid re-rating, with traders highlighting the strategic importance of the ClearPoint navigation system to the procedural rollout.

Arqit Quantum, Inc. engages in the provision of cybersecurity services via satellite and terrestrial forms. Its product is QuantumCloud which secures devices with cloud-based quantum encryption. The company was founded by David John Williams and David James Bestwick on April 26, 2021 and is headquartered in London, the United Kingdom.

Arqit Quantum Inc

Arqit Quantum is experiencing significant momentum as investors pivot toward quantum-safe cybersecurity, with the stock drawing attention for its low float and heavy institutional ownership. The community is actively discussing its potential for a parabolic squeeze, citing recent partnerships and the critical industry demand for post-quantum cryptographic solutions.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABD is experiencing heightened trading activity as the community remains divided over whether to capitalize on the biotech sector's volatility through short-term scalp trades or hold despite significant losses from the ETF's prolonged decline. Discussions are centered on the upcoming influence of key economic figures like Kevin Warsh, the impact of XBI's technical channel breakouts, and the recurring behavioral patterns traders are attempting to exploit during this period of market uncertainty.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are trending as investors weigh strong international revenue growth against uncertainty surrounding a potential Hantavirus outbreak and the company's early-stage vaccine research. The community is actively debating the stock's long-term outlook, with many focused on upcoming oncology data at the ASCO conference and the potential for a rapid vaccine response to emerging health threats.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABR management needs to start buying back at this level, still have $120 millions left , right?

Midnight Madness

StockTwits for iOS

Arbor Realty Trust Inc.

 management needs to start buying back at this level, still have $120 millions left , right?

Absolute Precisionist

@AbsolutePrecisionist perhaps they think they&#39;ll need to RS this thing. In which case just wait. Seems like a fast track to insolvency to me until non performing assets are resolved.

StockTwits Web

 perhaps they think they'll need to RS this thing. In which case just wait. Seems like a fast track to insolvency to me until non performing assets are resolved.

Dustin

@AbsolutePrecisionist all they need to do is sell off some non performing reo...and buy back shares. Which I am sure they are taking advantage of low rates. Ivan is shrewd and if market wants to take lower he will buy up shares for a song.  The remainder of the non performing loans they could take them all back and would be hard asset heavy...not great for earnings...and they don&#39;t want to be heavy into reo as a business model.

 all they need to do is sell off some non performing reo...and buy back shares. Which I am sure they are taking advantage of low rates. Ivan is shrewd and if market wants to take lower he will buy up shares for a song.  The remainder of the non performing loans they could take them all back and would be hard asset heavy...not great for earnings...and they don't want to be heavy into reo as a business model.